GlassScriptPhysician profile
Madelaine Chappus
NPI 1710574603
$2,667.97
in general payments reported to CMS, 2019-2025
21 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.26 · 2022: $19.34 · 2023: $247 · 2024: $2,148 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,330 · Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,329.75 |
| Food and Beverage | $1,300.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,881.23 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.55 | 2023-2024 | Lifevest |
| Medtronic, INC. | $148.79 | 2023 | Micra |
| Imperative Care, INC | $66.62 | 2025 | Symphony Catheter, Prodigy Catheter |
| Lilly USA, LLC | $52.74 | 2024 | Jardiance |
| Novo Nordisk INC | $48.56 | 2024-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $35.15 | 2024-2025 | Capvaxive, Gardasil 9, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.37 | 2025 | Xifaxan |
| Lexicon Pharmaceuticals, INC. | $32.58 | 2024 | |
| Cvrx, INC. | $28.64 | 2024 | Barostim Neo System |
| Corcept Therapeutics | $27.60 | 2024-2025 | Korlym |
| Ucb, INC. | $20.59 | 2025 | Nayzilam |
| Seqirus USA INC | $19.46 | 2025 | Flucelvax, Fluad |
| Veryan Medical Incorporated | $19.34 | 2022 | |
| Tactile Systems Technology INC | $18.26 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.94 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $14.46 | 2025 | |
| Aimmune Therapeutics, INC. | $14.06 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.32 | 2024 | Jardiance |
| Baxter Healthcare | $12.75 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Phathom Pharmaceuticals, INC. | $11.96 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madelaine Chappus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.